$0.65
6.62% yesterday
Nasdaq, May 20, 10:14 pm CET
ISIN
US46333X1081
Symbol
IRWD

Ironwood Pharmaceuticals Stock price

$0.65
-0.05 7.45% 1M
-2.87 81.47% 6M
-3.78 85.27% YTD
-5.77 89.84% 1Y
-10.74 94.27% 3Y
-11.25 94.52% 5Y
-11.10 94.45% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.04 6.62%
ISIN
US46333X1081
Symbol
IRWD
Sector
Industry

Key metrics

Market capitalization $105.57m
Enterprise Value $596.17m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 7.60
EV/Sales (TTM) EV/Sales 1.88
P/S ratio (TTM) P/S ratio 0.33
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -23.18%
Revenue (TTM) Revenue $317.68m
EBIT (operating result TTM) EBIT $83.94m
Free Cash Flow (TTM) Free Cash Flow $78.41m
Cash position $108.48m
EPS (TTM) EPS $-0.20
P/E forward 3.74
P/S forward 0.39
EV/Sales forward 2.19
Short interest 8.26%
Show more

Is Ironwood Pharmaceuticals a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Ironwood Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Ironwood Pharmaceuticals forecast:

5x Hold
100%

Analyst Opinions

5 Analysts have issued a Ironwood Pharmaceuticals forecast:

Hold
100%

Financial data from Ironwood Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
318 318
23% 23%
100%
- Direct Costs 1.98 1.98
10% 10%
1%
316 316
23% 23%
99%
- Selling and Administrative Expenses 120 120
24% 24%
38%
- Research and Development Expense 110 110
14% 14%
35%
86 86
32% 32%
27%
- Depreciation and Amortization 1.98 1.98
10% 10%
1%
EBIT (Operating Income) EBIT 84 84
33% 33%
26%
Net Profit -31 -31
97% 97%
-10%

In millions USD.

Don't miss a Thing! We will send you all news about Ironwood Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ironwood Pharmaceuticals Stock News

Neutral
Business Wire
14 days ago
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its first quarter 2025 results and recent business performance. “LINZESS demand continues to be strong, and we remain on track to meet our full-year 2025 guidance and ...
Neutral
Business Wire
20 days ago
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7th at 12:00 p.m. ET at the New York Hilton Midtown. A live webcast of Ironwood's fireside chat will be accessible through the Investors section of the company's website at www.ironwoodpharma.com. A ...
Neutral
Business Wire
26 days ago
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced it reiterates its full year 2025 LINZESS U.S. net sales and total Ironwood revenue guidance and raises its adjusted EBITDA guidance. Ironwood plans to report full fir...
More Ironwood Pharmaceuticals News

Company Profile

Ironwood Pharmaceuticals, Inc. is a commercial biotechnology company, which engages in the discovery, commercialization, and development of medicines. Its products include linaclotide, a guanylate cyclase type-C agonists which treats patients irritable bowel syndrome with constipation and chronic constipation. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook Jr., and Gina Bornino Miller on January 5, 1998 and is headquartered in Boston, MA.

Head office United States
CEO Thomas McCourt
Employees 253
Founded 1998
Website www.ironwoodpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today